Mycobacterium bovis Bacillus Calmette-Guerin (BCG) and BCG-based vaccines against tuberculosis

Seung Bin Cha, SungJae Shin

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Tuberculosis (TB) is the second leading infectious cause of mortality worldwide with about two million deaths per year. The only licensed TB vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG) shows limited protection efficacy suggesting an improved vaccination strategy is required. Recently, several TB vaccine candidates have entered clinical trials. These vaccine candidates are live mycobacterial vaccines designed to replace BCG or subunit vaccines designed to boost immunity induced by BCG. Vaccines with different strategy such as therapeutic vaccines, which can also be used in combination with drug therapy, are in the early stages of development to resolve latent TB or reactivation from the latent state. In this review, we discuss about development of BCG and BCG-based vaccines and further studies necessary for novel TB vaccine development to sterilize tuberculosis.

Original languageEnglish
Pages (from-to)236-243
Number of pages8
JournalJournal of Bacteriology and Virology
Volume44
Issue number3
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

BCG Vaccine
Tuberculosis Vaccines
Mycobacterium bovis
Bacillus
Tuberculosis
Vaccines
Latent Tuberculosis
Subunit Vaccines
Combination Drug Therapy
Immunity
Vaccination
Clinical Trials
Mortality

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Immunology
  • Virology

Cite this

@article{10e3ba3c7bf04d38a57d6cbd144c07ce,
title = "Mycobacterium bovis Bacillus Calmette-Guerin (BCG) and BCG-based vaccines against tuberculosis",
abstract = "Tuberculosis (TB) is the second leading infectious cause of mortality worldwide with about two million deaths per year. The only licensed TB vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG) shows limited protection efficacy suggesting an improved vaccination strategy is required. Recently, several TB vaccine candidates have entered clinical trials. These vaccine candidates are live mycobacterial vaccines designed to replace BCG or subunit vaccines designed to boost immunity induced by BCG. Vaccines with different strategy such as therapeutic vaccines, which can also be used in combination with drug therapy, are in the early stages of development to resolve latent TB or reactivation from the latent state. In this review, we discuss about development of BCG and BCG-based vaccines and further studies necessary for novel TB vaccine development to sterilize tuberculosis.",
author = "Cha, {Seung Bin} and SungJae Shin",
year = "2014",
month = "1",
day = "1",
doi = "10.4167/jbv.2014.44.3.236",
language = "English",
volume = "44",
pages = "236--243",
journal = "Journal of Bacteriology and Virology",
issn = "1598-2467",
publisher = "Chonnam National University Medical School",
number = "3",

}

Mycobacterium bovis Bacillus Calmette-Guerin (BCG) and BCG-based vaccines against tuberculosis. / Cha, Seung Bin; Shin, SungJae.

In: Journal of Bacteriology and Virology, Vol. 44, No. 3, 01.01.2014, p. 236-243.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Mycobacterium bovis Bacillus Calmette-Guerin (BCG) and BCG-based vaccines against tuberculosis

AU - Cha, Seung Bin

AU - Shin, SungJae

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Tuberculosis (TB) is the second leading infectious cause of mortality worldwide with about two million deaths per year. The only licensed TB vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG) shows limited protection efficacy suggesting an improved vaccination strategy is required. Recently, several TB vaccine candidates have entered clinical trials. These vaccine candidates are live mycobacterial vaccines designed to replace BCG or subunit vaccines designed to boost immunity induced by BCG. Vaccines with different strategy such as therapeutic vaccines, which can also be used in combination with drug therapy, are in the early stages of development to resolve latent TB or reactivation from the latent state. In this review, we discuss about development of BCG and BCG-based vaccines and further studies necessary for novel TB vaccine development to sterilize tuberculosis.

AB - Tuberculosis (TB) is the second leading infectious cause of mortality worldwide with about two million deaths per year. The only licensed TB vaccine, Mycobacterium bovis bacillus Calmette-Guerin (BCG) shows limited protection efficacy suggesting an improved vaccination strategy is required. Recently, several TB vaccine candidates have entered clinical trials. These vaccine candidates are live mycobacterial vaccines designed to replace BCG or subunit vaccines designed to boost immunity induced by BCG. Vaccines with different strategy such as therapeutic vaccines, which can also be used in combination with drug therapy, are in the early stages of development to resolve latent TB or reactivation from the latent state. In this review, we discuss about development of BCG and BCG-based vaccines and further studies necessary for novel TB vaccine development to sterilize tuberculosis.

UR - http://www.scopus.com/inward/record.url?scp=84907858328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907858328&partnerID=8YFLogxK

U2 - 10.4167/jbv.2014.44.3.236

DO - 10.4167/jbv.2014.44.3.236

M3 - Review article

VL - 44

SP - 236

EP - 243

JO - Journal of Bacteriology and Virology

JF - Journal of Bacteriology and Virology

SN - 1598-2467

IS - 3

ER -